Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital admission among higher-risk patients with COVID-19 in Wales: A retrospective cohort study

{ 'indexed': {'date-parts': [[2023, 2, 25]], 'date-time': '2023-02-25T05:30:36Z', 'timestamp': 1677303036165}, 'reference-count': 33, 'publisher': 'Elsevier BV', 'license': [ { 'start': { 'date-parts': [[2023, 2, 1]], 'date-time': '2023-02-01T00:00:00Z', 'timestamp': 1675209600000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'}], 'content-domain': { 'domain': [ 'clinicalkey.fr', 'clinicalkey.jp', 'clinicalkey.es', 'clinicalkey.com.au', 'clinicalkey.com', 'journalofinfection.com', 'elsevier.com', 'sciencedirect.com'], 'crossmark-restriction': True}, 'published-print': {'date-parts': [[2023, 2]]}, 'DOI': '10.1016/j.jinf.2023.02.012', 'type': 'journal-article', 'created': {'date-parts': [[2023, 2, 10]], 'date-time': '2023-02-10T10:47:06Z', 'timestamp': 1676026026000}, 'update-policy': 'http://dx.doi.org/10.1016/elsevier_cm_policy', 'source': 'Crossref', 'is-referenced-by-count': 1, 'title': 'Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing ' 'hospital admission among higher-risk patients with COVID-19 in Wales: A retrospective cohort ' 'study', 'prefix': '10.1016', 'author': [ {'given': 'Andrew', 'family': 'Evans', 'sequence': 'first', 'affiliation': []}, {'given': 'Cathy', 'family': 'Qi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Jubril Omololu', 'family': 'Adebayo', 'sequence': 'additional', 'affiliation': []}, {'given': 'Jonathan', 'family': 'Underwood', 'sequence': 'additional', 'affiliation': []}, {'given': 'James', 'family': 'Coulson', 'sequence': 'additional', 'affiliation': []}, {'given': 'Rowena', 'family': 'Bailey', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ronan', 'family': 'Lyons', 'sequence': 'additional', 'affiliation': []}, {'given': 'Adrian', 'family': 'Edwards', 'sequence': 'additional', 'affiliation': []}, {'given': 'Alison', 'family': 'Cooper', 'sequence': 'additional', 'affiliation': []}, {'given': 'Gareth', 'family': 'John', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ashley', 'family': 'Akbari', 'sequence': 'additional', 'affiliation': []}], 'member': '78', 'reference': [ { 'key': '10.1016/j.jinf.2023.02.012_bib1', 'unstructured': 'Department of Health and Social Care. Government launches COVID-19 ' 'antivirals taskforce to roll out innovative home treatments this autumn; ' '2021 [cited 2023 Jan 20]. Available from: ' '〈https://www.gov.uk/government/news/government-launches-covid-19-antivirals-taskforce-to-roll-out-innovative-home-treatments-this-autumn〉.'}, { 'key': '10.1016/j.jinf.2023.02.012_bib2', 'doi-asserted-by': 'crossref', 'first-page': '1941', 'DOI': '10.1056/NEJMoa2107934', 'article-title': 'Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody ' 'sotrovimab', 'volume': '385', 'author': 'Gupta', 'year': '2021', 'journal-title': 'N Engl J Med'}, { 'key': '10.1016/j.jinf.2023.02.012_bib3', 'doi-asserted-by': 'crossref', 'first-page': '509', 'DOI': '10.1056/NEJMoa2116044', 'article-title': 'Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients', 'volume': '386', 'author': 'Jayk Bernal', 'year': '2022', 'journal-title': 'N Engl J Med'}, { 'key': '10.1016/j.jinf.2023.02.012_bib4', 'doi-asserted-by': 'crossref', 'first-page': '1397', 'DOI': '10.1056/NEJMoa2118542', 'article-title': 'Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19', 'volume': '386', 'author': 'Hammond', 'year': '2022', 'journal-title': 'N Engl J Med'}, { 'key': '10.1016/j.jinf.2023.02.012_bib5', 'doi-asserted-by': 'crossref', 'first-page': '305', 'DOI': '10.1056/NEJMoa2116846', 'article-title': 'Early remdesivir to prevent progression to severe Covid-19 in ' 'outpatients', 'volume': '386', 'author': 'Gottlieb', 'year': '2022', 'journal-title': 'N Engl J Med'}, { 'issue': '23', 'key': '10.1016/j.jinf.2023.02.012_bib6', 'doi-asserted-by': 'crossref', 'DOI': '10.1056/NEJMoa2108163', 'article-title': 'REGEN-COV antibody combination and outcomes in outpatients with ' 'Covid-19', 'volume': '385', 'author': 'Weinreich', 'year': '2021', 'journal-title': 'N Engl J Med'}, { 'key': '10.1016/j.jinf.2023.02.012_bib7', 'first-page': '1', 'article-title': 'COVID-19 Genomics UK Consortium,et al., SARS-CoV-2 variant evasion of ' 'monoclonal antibodies based on in vitro studies', 'author': 'Cox', 'year': '2022', 'journal-title': 'Nat Rev Microbiol'}, { 'key': '10.1016/j.jinf.2023.02.012_bib8', 'unstructured': 'Roche. Ronapreve does not retain neutralising activity against the ' 'Omicron variant; 2021 [cited 2023 Jan 20] [internet]. Available from: ' '〈2021216_roche-statement-on-ronapreve-omicron.pdf〉.'}, { 'key': '10.1016/j.jinf.2023.02.012_bib9', 'unstructured': 'US Federal Drugs Administration. Coronavirus (COVID-19) update: FDA ' 'limits use of certain monoclonal antibodies to treat COVID-19 due to the ' 'Omicron variant; 2022 [cited 2023 Jan 20] [internet]. Available from: ' '〈https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-limits-use-certain-monoclonal-antibodies-treat-covid-19-due-omicron〉.'}, { 'key': '10.1016/j.jinf.2023.02.012_bib10', 'unstructured': 'World Health Organisation. Therapeutics and COVID-19: living guideline; ' '2022 [cited 2023 Jan 20] [internet]. Available from: ' '〈https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2022.5〉.'}, { 'key': '10.1016/j.jinf.2023.02.012_bib11', 'unstructured': 'Department of Health and Social Care. Highest-risk patients eligible for ' 'new COVID-19 treatments: a guide for patients; 2022 [cited 2023 Jan 20]. ' 'Available from: ' '〈https://www.gov.uk/government/publications/highest-risk-patients-eligible-for-covid-19-treatments-guide-for-patients/highest-risk-patients-eligible-for-new-covid-19-treatments-a-guide-for-patients〉.'}, { 'key': '10.1016/j.jinf.2023.02.012_bib12', 'unstructured': 'NHS England. Interim clinical commissioning policy: treatments for ' 'non-hospitalised patients with COVID-19; 2022 [cited 2023 Jan 20] ' '[internet]. Available from: ' '〈C1710-interim-clinical-commissioning-policy-treatments-for-non-hospitalised-patients-with-covid-19-nov-22.pdf〉 ' '(england.nhs.uk).'}, { 'key': '10.1016/j.jinf.2023.02.012_bib13', 'unstructured': 'NHS England. COVID-19 therapeutics (antivirals, neutralising monoclonal ' 'antibodies and interleukin 6 inhibitors); 2022 [cited 2023 Jan 20] ' '[internet]. Available from: ' '〈https://www.england.nhs.uk/statistics/statistical-work-areas/covid-therapeutics-antivirals-and-neutralising-monoclonal-antibodies/〉.'}, { 'key': '10.1016/j.jinf.2023.02.012_bib14', 'unstructured': 'Welsh Government. Weekly COVID-19 treatment counts by therapeutic agent ' 'in Wales; 2022 [cited 2023 Jan 20] [internet]. Available from: ' '〈https://statswales.gov.wales/Catalogue/Health-and-Social-Care/coronavirus-covid-19/covid-19-treatments-by-therapeutic-agent/weeklycovidtreatmentcounts-by-therapeuticagent〉.'}, { 'key': '10.1016/j.jinf.2023.02.012_bib15', 'doi-asserted-by': 'crossref', 'first-page': '157', 'DOI': '10.1186/1472-6963-9-157', 'article-title': 'The SAIL databank: building a national architecture for e-health ' 'research and evaluation', 'volume': '9', 'author': 'Ford', 'year': '2009', 'journal-title': 'BMC Health Serv Res'}, { 'issue': '100', 'key': '10.1016/j.jinf.2023.02.012_bib16', 'doi-asserted-by': 'crossref', 'first-page': '196', 'DOI': '10.1016/j.jbi.2014.01.003', 'article-title': 'A case study of the secure anonymous information linkage (SAIL) ' 'gateway: a privacy protecting remote access system for health related ' 'research and evaluation', 'volume': '50', 'author': 'Jones', 'year': '2014', 'journal-title': 'J Biomed Inform'}, { 'key': '10.1016/j.jinf.2023.02.012_bib17', 'doi-asserted-by': 'crossref', 'first-page': '3', 'DOI': '10.1186/1472-6947-9-3', 'article-title': 'The SAIL databank: linking multiple health and social care datasets', 'volume': '9', 'author': 'Lyons', 'year': '2009', 'journal-title': 'BMC Med Inform Decis Mak'}, { 'issue': '2', 'key': '10.1016/j.jinf.2023.02.012_bib18', 'doi-asserted-by': 'crossref', 'first-page': '209', 'DOI': '10.1016/j.healthplace.2011.09.006', 'article-title': 'Protecting health data privacy while using residence-based environment ' 'and demographic data', 'volume': '18', 'author': 'Rodgers', 'year': '2012', 'journal-title': 'Health Place'}, { 'issue': '4', 'key': '10.1016/j.jinf.2023.02.012_bib19', 'doi-asserted-by': 'crossref', 'first-page': '582', 'DOI': '10.1093/pubmed/fdp041', 'article-title': 'Residential anonymous linking fields (RALFs): a novel information ' 'infrastructure to study the interaction between the environment and ' 'individuals’ health', 'volume': '31', 'author': 'Rodgers', 'year': '2009', 'journal-title': 'J Public Health'}, { 'key': '10.1016/j.jinf.2023.02.012_bib20', 'unstructured': 'Welsh Government. Coronavirus (COVID-19) infection survey (positivity ' 'estimates): 27 March to 2 April 2022; 2022 [cited 2023 Jan 20] ' '[internet]. Available from: ' '〈https://www.gov.wales/coronavirus-covid-19-infection-survey-positivity-estimates-27-march-2-april-2022-html〉.'}, { 'key': '10.1016/j.jinf.2023.02.012_bib21', 'unstructured': 'Welsh Medicines Information Centre. National Antiviral Service Cymru ' '(NAVS) – information for members of the public; 2022 [cited 2023 Jan ' '20]. Available from: ' '〈https://www.wmic.wales.nhs.uk/navs-cymru/#:~:text=%E2%80%93%20Information%20for%20Members%20of%20the,not%20been%20admitted%20to%20hospital〉.'}, { 'key': '10.1016/j.jinf.2023.02.012_bib22', 'article-title': 'Effectiveness of paxlovid in reducing severe COVID-19 and mortality in ' 'high risk patients', 'author': 'Najjar-Debbiny', 'year': '2022', 'journal-title': 'Clin Infect Dis'}, { 'key': '10.1016/j.jinf.2023.02.012_bib23', 'doi-asserted-by': 'crossref', 'unstructured': 'Cheng M, Reyes C, Satram S, H. Birch, D.C. Gibbons, M. Drysdale, et al. ' 'Real-world effectiveness of sotrovimab for the early treatment of ' 'COVID-19 during SARS-CoV-2 Delta and Omicron waves in the United States. ' '[Preprint]. medRxiv 2022.09.07.22279497.', 'DOI': '10.1101/2022.09.07.22279497'}, { 'issue': '10', 'key': '10.1016/j.jinf.2023.02.012_bib24', 'doi-asserted-by': 'crossref', 'first-page': '2693', 'DOI': '10.1093/jac/dkac256', 'article-title': 'Real-world effectiveness of early remdesivir and sotrovimab in the ' 'highest-risk COVID-19 outpatients during the Omicron surge', 'volume': '77', 'author': 'Piccicacco', 'year': '2022', 'journal-title': 'J Antimicrob Chemother'}, { 'key': '10.1016/j.jinf.2023.02.012_bib25', 'article-title': 'Molnupiravir plus usual care versus usual care alone as early treatment ' 'for adults with COVID-19 at increased risk of adverse outcomes ' '(PANORAMIC): an open-label, platform-adaptive randomised controlled ' 'trial', 'author': 'Butler', 'year': '2022', 'journal-title': 'Lancet'}, { 'key': '10.1016/j.jinf.2023.02.012_bib26', 'article-title': 'Comparative effectiveness of sotrovimab and molnupiravir for prevention ' 'of severe covid-19 outcomes in patients in the community: observational ' 'cohort study with the OpenSAFELY platform', 'volume': '379', 'author': 'Zheng', 'year': '2022', 'journal-title': 'BMJ'}, { 'key': '10.1016/j.jinf.2023.02.012_bib27', 'article-title': 'Characteristics and outcomes of patients with COVID-19 at high-risk of ' 'disease progression receiving sotrovimab, oral antivirals or no ' 'treatment in England', 'author': 'Patel', 'year': '2022', 'journal-title': 'medRxiv'}, { 'key': '10.1016/j.jinf.2023.02.012_bib28', 'doi-asserted-by': 'crossref', 'first-page': '2458', 'DOI': '10.1111/ajt.17098', 'article-title': 'Real-world experience with available, outpatient COVID-19 therapies in ' 'solid organ transplant recipients during the omicron surge', 'volume': '22', 'author': 'Radcliffe', 'year': '2022', 'journal-title': 'Am J Transplant'}, { 'key': '10.1016/j.jinf.2023.02.012_bib29', 'doi-asserted-by': 'crossref', 'article-title': 'WHO’s therapeutics and COVID-19 living guideline on mAbs needs to be ' 'reassessed', 'author': 'Wu', 'year': '2022', 'journal-title': 'Lancet', 'DOI': '10.1016/S0140-6736(22)01938-9'}, { 'key': '10.1016/j.jinf.2023.02.012_bib30', 'doi-asserted-by': 'crossref', 'article-title': 'Merck’s COVID pill loses its lustre: what that means for the pandemic', 'author': 'Koslov', 'year': '2021', 'journal-title': 'Nature', 'DOI': '10.1038/d41586-021-03667-0'}, { 'key': '10.1016/j.jinf.2023.02.012_bib31', 'unstructured': 'Office for National Statistics. Coronavirus (COVID-19) latest insights: ' 'hospitals; 2023 [cited 2023 Jan 20] [internet]. Available from: ' '〈https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19latestinsights/hospitals〉.'}, { 'key': '10.1016/j.jinf.2023.02.012_bib32', 'unstructured': 'The National Institute for Health and Care Excellence. Draft guidance ' 'consultation: therapeutics for people with COVID-19; 2022 [cited 2023 ' 'Jan 20] [internet]. Available from: ' '〈https://www.nice.org.uk/guidance/gid-ta10936/documents/129〉.'}, { 'key': '10.1016/j.jinf.2023.02.012_bib33', 'unstructured': 'The Institute for Clinical and Economic Review. Report at a glance: ' 'COVID-19; 2022 [cited 2023 Jan 20]. Available from: ' '〈https://icer.org/wp-content/uploads/2022/05/COVID-19-RAAG_10May2022.pdf〉.'}], 'container-title': 'Journal of Infection', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S0163445323000828?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://api.elsevier.com/content/article/PII:S0163445323000828?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'deposited': { 'date-parts': [[2023, 2, 24]], 'date-time': '2023-02-24T15:41:42Z', 'timestamp': 1677253302000}, 'score': 1, 'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S0163445323000828'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2023, 2]]}, 'references-count': 33, 'alternative-id': ['S0163445323000828'], 'URL': 'http://dx.doi.org/10.1016/j.jinf.2023.02.012', 'relation': {}, 'ISSN': ['0163-4453'], 'subject': ['Infectious Diseases', 'Microbiology (medical)'], 'container-title-short': 'Journal of Infection', 'published': {'date-parts': [[2023, 2]]}, 'assertion': [ {'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'}, { 'value': 'Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and ' 'sotrovimab on preventing hospital admission among higher-risk patients with ' 'COVID-19 in Wales: A retrospective cohort study', 'name': 'articletitle', 'label': 'Article Title'}, {'value': 'Journal of Infection', 'name': 'journaltitle', 'label': 'Journal Title'}, { 'value': 'https://doi.org/10.1016/j.jinf.2023.02.012', 'name': 'articlelink', 'label': 'CrossRef DOI link to publisher maintained version'}, {'value': 'article', 'name': 'content_type', 'label': 'Content Type'}, { 'value': 'Crown Copyright © 2023 Published by Elsevier Ltd on behalf of The British ' 'Infection Association. All rights reserved.', 'name': 'copyright', 'label': 'Copyright'}]}